Patents by Inventor Jae Du Ha

Jae Du Ha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220105188
    Abstract: The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., EED or PRC2, utilizing cereblon E3 ubiquitin ligase, VHL E3 ubiquitin ligase, MDM2 E3 ubiquitin ligase, and cIAP E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.
    Type: Application
    Filed: February 7, 2020
    Publication date: April 7, 2022
    Inventors: Jong Yeon HWANG, Jae Du HA, Sung Yun CHO, Pilho KIM, Chang Soo YUN, Hyun Jin KIM, Sung Goo PARK, Byoung Chul PARK, Jeong Hoon KIM, Sunhong KIM
  • Patent number: 11192878
    Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: December 7, 2021
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon Hwang, Jae Du Ha, Sung Yun Cho, Pil Ho Kim, Chang Soo Yun, Chi Hoon Park, Chong Ock Lee, Sang Un Choi, Joo Youn Lee, Sunjoo Ahn
  • Patent number: 11084824
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: August 10, 2021
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Pilho Kim, Sung Yun Cho, Jae Du Ha, Hyoung Rae Kim, Jong Yeon Hwang, Chang Soo Yun, Hee Jung Jung, Chi Hoon Park, Chong Ock Lee, Chang Hoon Lee, Sunjoo Ahn
  • Publication number: 20200199129
    Abstract: The present invention relates to a pyrazolopyrimidine derivative, a preparation method thereof and a pharmaceutical composition comprising the same as an active ingredient for the prevention or treatment of cancer, autoimmune disease and brain disease. The pyrazolopyrimidine derivative of the present invention exhibits excellent Bruton's tyrosine kinase inhibition activity, so that it can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer, autoimmune disease and Parkinson's disease.
    Type: Application
    Filed: May 14, 2018
    Publication date: June 25, 2020
    Inventors: Pilho Kim, Sung Yun Cho, Jae Du Ha, Hyoung Rae Kim, Jong Yeon Hwang, Chang Soo Yun, Hee Jung Jung, Chi Hoon Park, Chong Ock Lee, Chang Hoon Lee, Sunjoo Ahn
  • Publication number: 20200062730
    Abstract: The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.
    Type: Application
    Filed: May 11, 2018
    Publication date: February 27, 2020
    Inventors: Jong Yeon HWANG, Jae Du HA, Sung Yun CHO, Pil Ho KIM, Chang Soo YUN, Chi Hoon PARK, Chong Ock LEE, Sang Un CHOI, Joo Youn LEE, Sunjoo AHN
  • Patent number: 10369149
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: August 6, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon Hwang, Hyoung Rae Kim, Jae Du Ha, Sung Yun Cho, Hee Jung Jung, Pilho Kim, Chang Soo Yun, Chong Ock Lee, Chi Hoon Park, Chong Hak Chae, Sunjoo Ahn
  • Patent number: 10100019
    Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: October 16, 2018
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Pilho Kim, Hyoung Rae Kim, Sung Yun Cho, Jae Du Ha, Hee Jung Jung, Chang Soo Yun, Jong Yeon Hwang, Chi Hoon Park, Chong Ock Lee, Sunjoo Ahn, Chong Hak Chae
  • Patent number: 10053458
    Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: August 21, 2018
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Chang Soo Yun, Hyoung Rae Kim, Sung Yun Cho, Hee Jung Jung, Kwangho Lee, Chong Hak Chae, Chong Ock Lee, Chi Hoon Park, Pilho Kim, Jong Yeon Hwang, Jae Du Ha, Sun Joo Ahn
  • Publication number: 20180111905
    Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: April 6, 2016
    Publication date: April 26, 2018
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Pilho Kim, Hyoung Rae Kim, Sung Yun Cho, Jae Du Ha, Hee Jung Jung, Chang Soo Yun, Jong Yeon Hwang, Chi Hoon Park, Chong Ock Lee, Sunjoo Ahn, Chong Hak Chae
  • Publication number: 20180104242
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: December 30, 2015
    Publication date: April 19, 2018
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon HWANG, Hyoung Rae KIM, Jae Du HA, Sung Yun CHO, Hee Jung JUNG, Pilho KIM, Chang Soo YUN, Chong Ock LEE, Chi Hoon PARK, Chong Hak CHAE, Sunjoo AHN
  • Publication number: 20170145007
    Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
    Type: Application
    Filed: May 21, 2015
    Publication date: May 25, 2017
    Inventors: Chang Soo YUN, Hyoung Rae KIM, Sung Yun CHO, Hee Jung JUNG, Kwangho LEE, Chong Hak CHAE, Chong Ock LEE, Chi Hoon PARK, Pilho KIM, Jong Yeon HWANG, Jae DU HA, Sun Joo AHN
  • Patent number: 9403831
    Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: August 2, 2016
    Assignees: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, HANDOK INC.
    Inventors: Hee Jung Jung, Jae Du Ha, Sung Yun Cho, Hyoung Rae Kim, Kwang Ho Lee, Chong Ock Lee, Sang Un Choi, Chi Hoon Park
  • Patent number: 9199944
    Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: December 1, 2015
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kwangho Lee, Hyoung Rae Kim, Chi Hoon Park, Chong Ock Lee, Jong Kook Lee, Hee Jung Jung, Sung Yun Cho, Chong Hak Chae, Sang Un Choi, Jae Du Ha
  • Publication number: 20150259350
    Abstract: The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
    Type: Application
    Filed: September 30, 2013
    Publication date: September 17, 2015
    Inventors: Hee Jung Jung, Jae Du Ha, Sung Yun Cho, Hyoung Rae Kim, Kwang Ho Lee, Chong Ock Lee, Sang Un Choi, Chi Hoon Park
  • Publication number: 20150152069
    Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.
    Type: Application
    Filed: February 9, 2015
    Publication date: June 4, 2015
    Inventors: Kwangho LEE, Hyoung Rae KIM, Chi Hoon PARK, Chong Ock LEE, Jong Kook LEE, Hee Jung JUNG, Sung Yun CHO, Chong Hak CHAE, Sang Un CHOI, Jae Du HA
  • Patent number: 8754209
    Abstract: Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms, Tie2, SAPK2a and Ret, inducing diseases caused by abnormal cell proliferation, the novel indazole derivatives can be used for the prevention or treatment of diseases caused by abnormal cell proliferation.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: June 17, 2014
    Assignees: Korea Institute of Science and Technology, Korea Research Institute of Chemical Technology, Korea Research Institute of Bioscience and Biotechnology
    Inventors: Tae Bo Sim, Jung Beom Son, Hwan Kim, Dong Sik Park, Hwan Geun Choi, Young Jin Ham, Jung Mi Hah, Kyung Ho Yoo, Chang Hyun Oh, So Ha Lee, Jae Du Ha, Sung Yun Cho, Byoung Mog Kwon, Dong Cho Han
  • Publication number: 20120130069
    Abstract: Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms, Tie2, SAPK2a and Ret, inducing diseases caused by abnormal cell proliferation, the novel indazole derivatives can be used for the prevention or treatment of diseases caused by abnormal cell proliferation.
    Type: Application
    Filed: December 4, 2009
    Publication date: May 24, 2012
    Inventors: Tae Bo Sim, Jung Beom Son, Hwan Kim, Dong Sik Park, Hwan Geun Choi, Young Jin Ham, Jung Mi Hah, Kyung Ho Yoo, Chang Hyun Oh, So Ha Lee, Jae Du Ha, Sung Yun Cho, Byoung Mog Kwon, Dong Cho Han